

TA-W No.	Subject firm	Location	Inv start date
98,319	EcoWater Systems LLC	Woodbury, MN	6/3/2022
98,320	Otis Worldwide Corporation	Farmington, CT	6/3/2022
98,321	Premier Glass USA, LLC	Park Hills, MO	6/3/2022
98,322	Eagle's Catch, LLLP	Ellsworth, IA	6/6/2022
98,323	Massachusetts Mutual Life Insurance Company	Springfield, MA	6/6/2022
98,324	Palisades Power Plant	Covert, MI	6/7/2022
98,325	Aisin Electronics, Inc	Stockton, CA	6/10/2022
98,326	Electronic Arts Inc	Austin, TX	6/13/2022
98,327	Heartland Construction	Georgetown, TX	6/13/2022
98,328	Parkdale Mills Plant #39	Alexander City, AL	6/13/2022
98,329	Kerry Inc	Clark, NJ	6/14/2022
98,330	Thule, Inc	Seymour, CT	6/14/2022
98,331	Tripwire	Portland, OR	6/14/2022
98,332	Medline Industries, Inc	Lithia Springs, GA	6/15/2022
98,333	Parkdale Mills	Galax, VA	6/15/2022
98,334	SASOL Chemicals (USA) LLC, Oil City Plant, Sasol (USA) Corporation.	Oil City, PA	6/15/2022
98,335	BioReliance Corporation	Rockville, MD	6/17/2022
98,336	Imerys Carbonates USA	Cockeysville, MD	6/17/2022
98,337	Wells Fargo	Frederick, MD	6/17/2022
98,338	Wisetek Solutions	Hyattsville, MD	6/17/2022
98,339	Boston Scientific Company	San Jose, CA	6/22/2022
98,340	Small Wells Vehicle Electronics	Fond du Lac, WI	6/22/2022
98,341	Advanced Input Systems	Frankenmuth, MI	6/23/2022
98,342	R.A. Phillips Industries, Inc	Santa Fe Springs, CA	6/23/2022
98,343	Prevost Car, Prevost Canada, Volvo Group	Plattsburgh, NY	6/23/2022
98,344	PayPal, Inc	LaVista, NE	6/24/2022
98,345	IEE Sensing, Inc	Auburn Hills, MI	6/27/2022
98,346	Urschel Tool Company	Cranston, RI	6/28/2022
98,347	Vestas Towers America, Inc	Pueblo, CO	6/29/2022
98,348	Waupaca Foundry, Inc	Etowah, TN	6/29/2022
98,349	Medical Component Specialists, Inc	Providence, RI	6/30/2022
98,350	Michael Food	David City, NE	6/30/2022
98,351	Mitsubishi Electric Automotive America, Inc	Maysville, KY	6/30/2022
98,352	Solar Seal LLC	South Easton, MA	6/30/2022

A record of these investigations and petitions filed are available, subject to redaction, on the Department's website <https://www.dol.gov/agencies/eta/tradeact> under the searchable listing or by calling the Office of Trade Adjustment Assistance toll free at 888-365-6822.

Signed at Washington, DC, this 7th day of July 2022.

Hope D. Kinglock,

Certifying Officer, Office of Trade Adjustment Assistance.

[FR Doc. 2022-15254 Filed 7-15-22; 8:45 am]

BILLING CODE 4510-FN-P

NUCLEAR REGULATORY COMMISSION

[Docket No. 50-609; NRC-2013-0235]

Northwest Medical Isotopes, LLC Medical Radioisotope Production Facility

AGENCY: Nuclear Regulatory Commission.

ACTION: Termination of construction permit.

SUMMARY: The U.S. Nuclear Regulatory Commission (NRC) is terminating the

Northwest Medical Isotopes, LLC (NWMI) Medical Radioisotope Production Facility (RPF) construction permit (permit) designated as CPMIF-002. The permit authorized NWMI to construct the RPF in Columbia, Missouri. Construction was not initiated for the RPF, and nuclear materials were never procured or possessed under this permit. Consequently, the RPF site is approved for unrestricted use.

DATES: The letter terminating Construction Permit No. CPMIF-002 was issued on July 11, 2022.

ADDRESSES: Please refer to Docket ID NRC-2013-0235 when contacting the NRC about the availability of information regarding this document. You may obtain publicly available information related to this document using any of the following methods:

- *Federal Rulemaking Website:* Go to <https://www.regulations.gov> and search for Docket ID NRC-2013-0235. Address questions about Docket IDs in *Regulations.gov* to Stacy Schumann; telephone: 301-415-0624; email: Stacy.Schumann@nrc.gov. For technical questions, contact the individual listed in the **FOR FURTHER INFORMATION CONTACT** section of this document.

- *NRC's Agencywide Documents Access and Management System (ADAMS):* You may obtain publicly available documents online in the ADAMS Public Documents collection at <https://www.nrc.gov/reading-rm/adams.html>. To begin the search, select "Begin Web-based ADAMS Search." For problems with ADAMS, please contact the NRC's Public Document Room (PDR) reference staff at 1-800-397-4209, 301-415-4737, or by email to PDR.Resource@nrc.gov. For the convenience of the reader, instructions about obtaining materials referenced in this document are provided in the "Availability of Documents" section.

- *NRC's PDR:* You may examine and purchase copies of public documents, by appointment, at the NRC's PDR, Room P1 B35, One White Flint North, 11555 Rockville Pike, Rockville, Maryland 20852. To make an appointment to visit the PDR, please send an email to PDR.Resource@nrc.gov or call 1-800-397-4209 or 301-415-4737, between 8:00 a.m. and 4:00 p.m. Eastern Time (ET), Monday through Friday, except Federal holidays.

FOR FURTHER INFORMATION CONTACT: Michael Balazik, Office of Nuclear Reactor Regulation, U.S. Nuclear

Regulatory Commission, Washington, DC 20555-0001; telephone: 301-415-2856; email: *Michael.Balazik@nrc.gov*.

SUPPLEMENTARY INFORMATION:

I. Introduction

On May 9, 2018, the NRC issued Construction Permit No. CPMIF-002 to NWMI to authorize the construction of the RPF. Since the issuance of the permit, NWMI has not begun construction of the RPF or procured nuclear materials for use under the permit. By letter dated February 7, 2022, NWMI stated that the RPF will not be constructed and requested that the NRC terminate Construction Permit No. CPMIF-002. NWMI also stated that no physical or principal activities authorized by the permit, other than a geotechnical survey, were performed at the permitted site at Lot 15 of Discovery Ridge in Columbia, Missouri. The geotechnical survey was required by condition 3.G of the permit and consisted of borings used to determine the local soil stratigraphy. NWMI further stated that no other work was conducted at the site and that the University of Missouri continues to own the land, which remains undeveloped.

II. License Termination

Termination of licenses and permits issued under part 50 of title 10 of the *Code of Federal Regulations* (10 CFR) is governed by 10 CFR 50.82, "Termination of license." As discussed in "Current NRC Staff Views on Applying the Deferred Plant Policy Statement to Part 52 Plants," the NRC staff does not apply the requirements for license termination in 10 CFR 50.82 to facilities that have not begun operation. Additionally, there was no construction associated with the NWMI RPF permit and nuclear materials were never procured or possessed under the permit. As such, with no radiological contamination associated with the

permit, the RPF site may be released for unrestricted use pursuant to 10 CFR 20.1402, "Radiological criteria for unrestricted use."

III. Environmental Review

NWMI seeks to terminate the RPF permit for which construction never commenced and nuclear materials were never procured or brought on site. Terminating a construction permit is a licensing action that would ordinarily require an environmental assessment under 10 CFR 51.21, "Criteria for and identification of licensing and regulatory actions requiring environmental assessments," unless a categorical exclusion in 10 CFR 51.22, "Criterion for categorical exclusion; identification of licensing and regulatory actions eligible for categorical exclusion or otherwise not requiring environmental review," paragraph (c) applies and no special circumstances under 10 CFR 51.22(b) exist. Actions listed in 10 CFR 51.22(c) were previously found by the Commission to be part of a category of actions that "does not individually or cumulatively have a significant effect on the human environment."

The categorical exclusion identified in 10 CFR 51.22(c)(20) is:

Decommissioning of sites where licensed operations have been limited to the use of—

- (i) Small quantities of short-lived radioactive materials;
- (ii) Radioactive materials in sealed sources, provided there is no evidence of leakage of radioactive material from these sealed sources; or
- (iii) Radioactive materials in such a manner that a decommissioning plan is not required by 10 CFR 30.36(g)(1), 40.42(g)(1), or 70.38(g)(1) and the NRC has determined that the facility meets the radiological criteria for unrestricted use in 10 CFR 20.1402 without further remediation or analysis.

This categorical exclusion encompasses decommissioning of sites where contamination from radioactive materials is determined to be nominal.

In the case of the NWMI RPF, no associated radiological contamination exists because construction never commenced and nuclear material was never procured or brought on site. As a result, a decommissioning plan for this site is not required by subparagraph (g)(1) of 10 CFR 30.36, "Expiration and termination of licenses and decommissioning of sites and separate buildings or outdoor areas," subparagraph (g)(1) of 10 CFR 40.42, "Expiration and termination of licenses and decommissioning of sites and separate buildings or outdoor areas," or subparagraph (g)(1) of 10 CFR 70.38, "Expiration and termination of licenses and decommissioning of sites and separate buildings or outdoor areas," and the site meets the radiological criteria for unrestricted use in 10 CFR 20.1402 without further remediation or analysis. Further, no special circumstances under 10 CFR 51.22(b) exist. The factors listed in 10 CFR 51.22(c)(20) are consistent with the circumstances here because there is no environmental impact associated with terminating the NWMI RPF permit, which is even less than the nominal impacts anticipated by the categorical exclusion. Therefore, application of the categorical exclusion to the termination of the NWMI RPF permit is warranted. Consequently, pursuant to 10 CFR 51.22(b), no environmental impact statement or environmental assessment need be prepared in connection with the termination of Construction Permit No. CPMIF-002.

IV. Availability of Documents

The documents identified in the following table are available to interested persons through ADAMS, as indicated.

Document	ADAMS access- sion No.
U.S. Nuclear Regulatory Commission, Northwest Medical Isotopes, LLC—Termination of Construction Permit No. CPMIF-002 (EPID No. L-2022-LLL-0007), dated July 11, 2022.	ML22147A157
Northwest Medical Isotopes, LLC, Request for Termination of Northwest Medical Isotopes, LLC (NWMI) Construction Permit No. CPMIF-002 (Docket No. 50-609), dated February 7, 2022.	ML22084A004
U.S. Nuclear Regulatory Commission, Construction Permit No. CPMIF-002 for Northwest Medical Isotopes, LLC, Docket No. 50-609, Medical Radioisotope Production Facility, dated May 9, 2018.	ML18037A468
U.S. Nuclear Regulatory Commission, Current NRC Staff Views on Applying the Deferred Plant Policy Statement to Part 52 Plants, dated March 6, 2018.	ML18065B257

V. Conclusion

As previously discussed, the Commission has determined that the NWMI RPF permit termination request

meets the categorical exclusion criteria set forth in 10 CFR 51.22(c)(20) and that the unrestricted use criteria pursuant to 10 CFR 20.1402 are met.

The Commission grants NWMI's request to terminate Construction Permit No. CPMIF-002. This license termination was effective upon NWMI's

receipt of the NRC's termination letter, dated July 11, 2022.

Dated: July 13, 2022.

For the Nuclear Regulatory Commission.

Joshua M. Borroneo,

Chief, Non-Power Production and Utilization Facility Licensing Branch, Division of Advanced Reactors and Non-Power Production and Utilization Facilities, Office of Nuclear Reactor Regulation.

[FR Doc. 2022-15282 Filed 7-15-22; 8:45 am]

BILLING CODE 7590-01-P

SECURITIES AND EXCHANGE COMMISSION

Sunshine Act Meetings

TIME AND DATE: 2:00 p.m. on Thursday, July 21, 2022.

PLACE: The meeting will be held via remote means and/or at the Commission's headquarters, 100 F Street NE, Washington, DC 20549.

STATUS: This meeting will be closed to the public.

MATTERS TO BE CONSIDERED:

Commissioners, Counsel to the Commissioners, the Secretary to the Commission, and recording secretaries will attend the closed meeting. Certain staff members who have an interest in the matters also may be present.

In the event that the time, date, or location of this meeting changes, an announcement of the change, along with the new time, date, and/or place of the meeting will be posted on the Commission's website at <https://www.sec.gov>.

The General Counsel of the Commission, or his designee, has certified that, in his opinion, one or more of the exemptions set forth in 5 U.S.C. 552b(c)(3), (5), (6), (7), (8), 9(B) and (10) and 17 CFR 200.402(a)(3), (a)(5), (a)(6), (a)(7), (a)(8), (a)(9)(ii) and (a)(10), permit consideration of the scheduled matters at the closed meeting.

The subject matter of the closed meeting will consist of the following topics:

- Institution and settlement of injunctive actions;

- Institution and settlement of administrative proceedings;

- Resolution of litigation claims; and
- Other matters relating to examinations and enforcement proceedings.

At times, changes in Commission priorities require alterations in the scheduling of meeting agenda items that may consist of adjudicatory, examination, litigation, or regulatory matters.

CONTACT PERSON FOR MORE INFORMATION: For further information; please contact

Vanessa A. Countryman from the Office of the Secretary at (202) 551-5400.

Authority: 5 U.S.C. 552b.

Dated: July 14, 2022.

Vanessa A. Countryman,

Secretary.

[FR Doc. 2022-15399 Filed 7-14-22; 4:15 pm]

BILLING CODE 8011-01-P

SECURITIES AND EXCHANGE COMMISSION

[SEC File No. 270-464, OMB Control No. 3235-0527]

Submission for OMB Review; Comment Request; Extension: Rule 7d-2

Upon Written Request, Copies Available From: Securities and Exchange Commission, Office of FOIA Services, 100 F Street NE, Washington, DC 20549-2736

Notice is hereby given that, pursuant to the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520), the Securities and Exchange Commission (the "Commission") is soliciting comments on the collection of information summarized below. The Commission plans to submit this existing collection of information to the Office of Management and Budget for extension and approval.

In Canada, as in the United States, individuals can invest a portion of their earnings in tax-deferred retirement savings accounts ("Canadian retirement accounts"). These accounts, which operate in a manner similar to individual retirement accounts in the United States, encourage retirement savings by permitting savings on a tax-deferred basis. Individuals who establish Canadian retirement accounts while living and working in Canada and who later move to the United States ("Canadian-U.S. Participants" or "participants") often continue to hold their retirement assets in their Canadian retirement accounts rather than prematurely withdrawing (or "cashing out") those assets, which would result in immediate taxation in Canada.

Once in the United States, however, these participants historically have been unable to manage their Canadian retirement account investments. Most investment companies ("funds") that are "qualified companies" for Canadian retirement accounts are not registered under the U.S. securities laws. Securities of those unregistered funds, therefore, generally cannot be publicly offered and sold in the United States without violating the registration requirement of the Investment Company

Act of 1940 ("Investment Company Act").¹ As a result of this registration requirement, Canadian-U.S. Participants previously were not able to purchase or exchange securities for their Canadian retirement accounts as needed to meet their changing investment goals or income needs.

The Commission issued a rulemaking in 2000 that enabled Canadian-U.S. Participants to manage the assets in their Canadian retirement accounts by providing relief from the U.S. registration requirements for offers of securities of foreign issuers to Canadian-U.S. Participants and sales to Canadian retirement accounts.² Rule 7d-2 under the Investment Company Act³ permits foreign funds to offer securities to Canadian-U.S. Participants and sell securities to Canadian retirement accounts without registering as investment companies under the Investment Company Act.

Rule 7d-2 contains a "collection of information" requirement within the meaning of the Paperwork Reduction Act of 1995.⁴ Rule 7d-2 requires written offering materials for securities offered or sold in reliance on that rule to disclose prominently that those securities and the fund issuing those securities are not registered with the Commission, and that those securities and the fund issuing those securities are exempt from registration under U.S. securities laws. Rule 7d-2 does not require any documents to be filed with the Commission.

Rule 7d-2 requires written offering documents for securities offered or sold in reliance on the rule to disclose prominently that the securities are not registered with the Commission and may not be offered or sold in the United States unless registered or exempt from registration under the U.S. securities laws, and also to disclose prominently that the fund that issued the securities is not registered with the Commission. The burden under the rule associated with adding this disclosure to written offering documents is minimal and is non-recurring. The foreign issuer,

¹ 15 U.S.C. 80a. In addition, the offering and selling of securities that are not registered pursuant to the Securities Act of 1933 ("Securities Act") is generally prohibited by U.S. securities laws. 15 U.S.C. 77.

² See Offer and Sale of Securities to Canadian Tax-Deferred Retirement Savings Accounts, Release Nos. 33-7860, 34-42905, IC-24491 (June 7, 2000) [65 FR 37672 (June 15, 2000)]. This rulemaking also included new rule 237 under the Securities Act, permitting securities of foreign issuers to be offered to Canadian-U.S. Participants and sold to Canadian retirement accounts without being registered under the Securities Act. 17 CFR 230.237.

³ 17 CFR 270.7d-2.

⁴ 44 U.S.C. 3501-3502.